INTRODUCTION
============

Rapid and accurate diagnosis of infection and control measures are critical for preventing the spread of Middle East respiratory syndrome coronavirus (MERS-CoV) \[[@B1]\]. For laboratory diagnosis of MERS-CoV infection, lower respiratory samples are preferred irrespective of the length of time between symptom onset and sample collection \[[@B2]\]. Real-time reverse transcription PCR (rRT-PCR) with sputum samples is commonly used to diagnose MERS-CoV infection.

If a negative result is obtained for patients with a high index of suspicion for MERS-CoV infection, additional samples should be collected and tested \[[@B3]\]. A series of negative results does not rule out the possibility of MERS-CoV infection \[[@B1][@B3]\]. Possible explanations for false-negative MERS-CoV test results include low viral load very early or late in the illness, inadequate sputum samples due to poor sample collection from patients with dry cough or no cough, inappropriate sample handling or shipping, and technical issues, such as viral genome mutation or PCR inhibition \[[@B3]\]. Sufficient nucleic acid extraction and the removal of substances that inhibit amplification are critical factors influencing the detection of MERS-CoV by rRT-PCR \[[@B4]\]. However, rRT-PCR of sputum samples yields conflicting results owing to the difficulty of extracting RNA from sputum containing mucus. Many reports have indicated that lower respiratory samples such as bronchoalveolar lavage (BAL) fluid and sputum contain the highest viral loads \[[@B3][@B5][@B6][@B7]\]. However, one report indicated that no significant difference occurred in viral load cycle threshold (Ct) values between sputa and nasopharyngeal aspirates (NPAs) \[[@B8]\]. For this reason, sputum sample homogenization is desirable prior to isolating nucleic acids for MERS-CoV rRT-PCR. In this study, we compared three different sputum homogenization methods and identified an optimal homogenization method prior to the nucleic acid isolation from sputum samples.

METHODS
=======

1. Sputum quality
-----------------

Forty-eight consecutive sputum samples sent to the laboratory for MERS-CoV rRT-PCR testing were evaluated in terms of the number of white blood cells, squamous epithelial cells, and ciliated columnar epithelial cells. The sputum samples were graded by using Murray and Washington\'s grading system \[[@B9]\].

2. Preparation of virus-spiked sputum samples
---------------------------------------------

An inactivated viral culture of MERS-CoV was provided by the Division of Respiratory Viruses (Center for Infectious Diseases, Korean National Institute of Health, Korean Center for Disease Control). The Korean National Institute of Health did not disclose the exact titer of the cultured MERS-CoV. Since other viral respiratory pathogens and bacterial pathogens should be considered during diagnosis \[[@B2]\], we evaluated whether the three homogenization methods have an adverse impact on the detection of other respiratory viruses. For this reason, we evaluated three homogenization methods using NPA samples that were found to contain various respiratory viruses using the Anyplex II RV16 Detection kit (Seegene, Seoul, Korea). Next, we evaluated the three homogenization methods using sputum samples spiked with a 1:10 or 1:1,000 dilution of viral culture mixed with an identical volume of sputum. Finally, we evaluated each homogenization method using virus-spiked sputum samples prepared by adding one volume of 1:100 diluted inactivated viral culture to nine volumes of clinical sample (i.e., sputum or BAL).

3. Sputum-homogenization methods
--------------------------------

Sputum samples were pretreated by using one of three methods. The first method involved proteinase K and DNase I treatment (PK-DNase), as recommended by the NucliSENS easyMAG protocol (bioMérieux SA, Marcy-l\'Etoile, France). One hundred microliters of proteinase K (1 mg proteinase K/1 mL proteinase K buffer; Promega, Madison, WI, USA) was added to 100 µL of sample and incubated for 15 min at 55℃. The samples were mixed by vortexing every 5 min. Subsequently, a 20-µL of DNase I solution (1 U/µL) was added for every 100 µL of sample, followed by incubation at 37℃ for 30 min. In the second method, sputum samples were mixed with an equal volume of phosphate-buffered saline (PBS). In the third method, the sputum samples were mixed with an equal volume of *N*-acetyl-L-cysteine (NALC) in sodium citrate solution (prepared by dissolving 0.5g NALC in each 100 mL of 1.47% sodium citrate solution). Following the second and third methods, the samples were mixed by vortexing for 1 min.

4. RNA extraction and MERS-CoV rRT-PCR testing
----------------------------------------------

RNA was extracted as described previously \[[@B10]\] by using the NucliSENS easyMAG system (bioMérieux SA, Marcy-l\'Etoile, France). RNA from each pretreated sample (500 µL) was eluted in a 50-µL volume. Extracted RNA was tested by rRT-PCR using Anyplex II RV16 Detection kit (Seegene) for the preliminary test, or by rRT-PCR using DiaPlexQ MERS Virus Detection kit (SolGent, Daejeon, Korea) with Bio-Rad CFX96 instrument (Bio-Rad, Hercules, CA, USA). The sequences of the primers and probes used with the DiaPlexQ kit covered the same general regions of the *upE* and *ORF1a* transcripts.

5. Statistical analysis
-----------------------

Quantitative results were expressed as mean±SD, and groups were compared by using the one-sample t-test. *P* values \<0.05 were considered statistically significant. MedCalc software version 16.2 (MedCalc Software bvba, Ostend, Belgium) was used for statistical analysis.

RESULTS
=======

According to Murray and Washington\'s grading system \[[@B9]\], among the 48 sputum samples tested, 18 (37.5%) belonged to group 1, 6 (12.5%) belonged to group 3, 2 (4.2%) belonged to group 4, 5 (10.4%) belonged to group 5, and 17 (35.4%) belonged to group 6. Thirty-two samples (66.7%), including 20 from groups 1--3, harbored a detectable quantity of ciliated columnar epithelial cells. Seventeen samples (35.4%) harbored identifiable proteinaceous mucous threads (viewed via light microscopy).

The efficacies of the three homogenization methods tested with NPA samples are summarized in [Table 1](#T1){ref-type="table"}. For DNA respiratory viruses (such as adenovirus and human bocavirus), PK-DNase treatment caused a slight increase in Ct values compared with PBS or NALC treatment. When we additionally tested six adenovirus-positive NPAs and five bocavirus-positive NPAs, the Ct values obtained following PBS preparation were 1.50--6.18 (median 5.42) and 1.60--7.61 (median 3.4) lower, respectively, than those obtained following PK-DNase preparation. Among the 10 samples derived from RNA respiratory viruses, the minimum Ct values resulted from PK-DNase treatment of three samples, PBS treatment of five samples, and NALC treatment of two samples.

Using identical volumes of sputum and inactivated viral culture diluted 1:10 or 1:1,000, the effects of each homogenization method on the MERS-CoV rRT-PCR results were evaluated ([Table 2](#T2){ref-type="table"}). Using a 1:10 dilution of inactivated viral culture, all samples treated with PK-DNase exhibited lower Ct values than those subjected to PBS or NALC treatment. The differences in Ct values between samples treated with PK-DNase or PBS were 5.4--7.8 for *upE* and 4.4--6.8 for *ORF1a*, while those for samples treated with PK-DNase or NALC were 4.7--5.8 for *upE* and 4.4--5.6 for *ORF1a*. Using the same volume of a 1:1,000 dilution of inactivated viral culture, one purulent sputum sample showed a false-negative result after PBS treatment. The Ct values of the other two sputum samples were similar following PK-DNase, PBS, and NALC treatments.

Using a one-tenth volume of a 1:1,000 dilution of inactivated viral culture (to simulate conditions comparable to those of real clinical samples), the effects of each method on the MERS-CoV rRT-PCR results were evaluated ([Table 3](#T3){ref-type="table"}). Among the three sputum samples, false-negative results were detected in two samples following PBS treatment and in three samples after NALC treatment ([Table 3](#T3){ref-type="table"}). Although the Ct values after PK-DNase treatment tended to be lower than those following PBS or NALC treatment, the values for BAL samples did not differ markedly depending on the homogenization method used.

To assess statistical significance, we tested 15 additional spiked samples, which were prepared by adding a one-tenth volume of 1:1,000 diluted viral culture ([Table 4](#T4){ref-type="table"}). Among the 15 spiked sputum samples prepared in duplicate (30 total samples), false-negative results were detected in five samples (16.7%) using the PBS method and in four samples (13.3%) using the NALC method. The ranges of Ct values for *upE* from sputum samples were 31.1--35.4 using the PK-DNase method, 34.7--39.0 using the PBS method, and 33.9--38.6 using the NALC method. Compared with the control, which were prepared by adding a one-tenth volume of 1:1,000 diluted viral culture to PBS solution, the ranges of Ct values following the PBS and NALC methods significantly differed from the mean Ct value (33.2) of the control (both *P*\<0.0001).

DISCUSSION
==========

For the extraction of MERS-CoV RNA from sputum sample, homogenization of sputum by PK-DNase I treatment was superior to treatment with PBS or NALC and sodium citrate. Proteinase K is a serine protease that exhibits broad cleavage specificity \[[@B11]\]. The enzyme cleaves peptide bonds adjacent to carboxylic group of aliphatic and aromatic amino acids and is useful for the general digestion of proteins in biological samples. Moreover, proteinase K degrades any RNases present in samples, preventing RNA degradation. Viral nucleic acids are protected from DNase I degradation by the viral protein capsids, although some enveloped viruses may be lost \[[@B12]\]. The genomes of DNA viruses such as adenovirus and bocavirus can be affected by proteinase K and DNase I, possibly owing to the digestion of viral capsid proteins by proteinase K and subsequent degradation of genomic DNA by DNase I.

Confirmation of probable or suspected MERS-CoV infection based on clinical and epidemiological criteria can only be accomplished through laboratory testing. However, other viral respiratory pathogens and bacterial pathogens should be considered during diagnosis \[[@B3]\]. When using lower respiratory samples originally earmarked for MERS-CoV testing, other viral respiratory pathogens should be tested for routine diagnostic processes. Because the ability to detect DNA respiratory viruses can be reduced by DNase I treatment, proteinase K treatment alone is worth considering for the routine detection of respiratory viruses from sputum samples.

The United States Centers for Disease Control and Prevention recommends that respiratory samples be extracted by using either the NucliSENS easyMAG system or MagNA Pure Compact Nucleic Acid Isolation kit \[[@B2]\]. Sputum samples categorized into groups 4--5 according to Murray and Washington\'s grading system \[[@B9]\] usually cannot undergo automated extraction owing to high viscosity and, thus, require a pre-homogenization process. Treatment with PBS or NALC and sodium citrate occasionally produces false-negative results with purulent sputum. Adding PBS and mixing via vortexing are necessary to culture respiratory viruses from sputum, and this procedure offers the advantage of involving minimum sample handling. However, thoroughly homogenizing thick or purulent sputum using this method is problematic. Because viral isolation by cell culture is not recommended for the routine confirmation of cases of MERS-CoV \[[@B2][@B3]\], the PBS plus vortexing method for processing sputum samples is not suitable for detecting MERS-CoV by rRT-PCR. Previously, it was reported that NALC and sodium citrate treatment (without NaOH) did not damage mycobacterial mRNA or rRNA in sputum samples \[[@B13]\]. NALC and sodium citrate solutions are readily available in clinical microbiology laboratories. Treatment with NALC and sodium citrate solution resulted in complete homogenization of sputum samples, including purulent sputum. However, this method is not suitable for detecting RNA targets in purulent sputum. Because proteinase K treatment requires heat inactivation of potential pathogens (incubation for 15 min at 55℃), this method offers additional laboratory safety.

Only 10% of sputum samples sent for MERS-CoV rRT-PCR testing were clinically relevant in terms of bacterial culture (group 5 according to Murray and Washington\'s grading system \[[@B9]\]). Among patients infected with MERS-CoV, a dry cough is more common than a productive cough \[[@B16][@B17]\]. Therefore, optimum sample collection is not feasible for patients unable to produce sputum. However, two thirds of sputum samples in our study contained identifiable ciliated columnar epithelial cells. Dipeptidyl peptidase 4, the human receptor for MERS-CoV \[[@B16]\], is expressed in type I and II alveolar cells, ciliated or non-ciliated bronchial epithelial cells, and bronchial submucosal glands \[[@B18][@B19]\]. Although it is difficult to obtain high-quality sputum from patients with no cough or a dry cough, obtaining and testing sputum samples containing ciliated columnar epithelial cells is recommended, if possible.

Our study has several limitations. First, it was performed by using spiked sputum samples; thus, our results may differ from those obtained by using authentic MERS-CoV-positive samples. However, the spiked sputum samples were similar to real sputum samples, as they were produced by adding a one-tenth volume of spiked viral solution to total sputum samples. Second, we tested a relatively small number of sputum samples under each test condition. Therefore, our findings should be confirmed by additional, larger studies.

In conclusion, the PK-DNase I treatment is suitable for the homogenization of sputum prior to RNA extraction for MERS-CoV rRT-PCR detection. Furthermore, adequate sputum homogenization prior to the isolation of nucleic acids is critical for accurate diagnosis of MERS-CoV infection.
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###### Cycle threshold (Ct) values following three homogenization methods used before Anyplex II RV16 detection of respiratory viruses in nasopharyngeal aspirates by rRT-PCR

![](alm-36-457-i001)

  Homogenization by     Respiratory virus (N)                                                                      
  --------------------- ----------------------- ----------- ----------- ------ ----------- ----------- ----------- ------
  PK-DNase I            35.6                    26.5/29.9   20.8/42.6   33.4   31.2/42.7   32.7/37.4   35.8/40.4   42.2
  PBS                   34.1                    21.6/28.3   19.8/41.9   31.7   33.2/44.3   35.8/35.4   37.0/37.3   38.3
  NALC-sodium citrate   33.1                    22.4/28.6   21.1/42.0   32.3   30.8/45.1   35.0/35.6   36.3/35.1   39.2

Abbreviations: rRT-PCR, Real-time reverse transcription PCR; PK, proteinase K; PBS, phosphate-buffered saline; NALC, *N*-acetyl-L-cysteine; ADV, adenovirus; BoV, human bocavirus; INF A, influenza virus A; RhinoV, rhinovirus; CoV, human coronavirus; RSV, respiratory syncytial virus; hMPV, human metapneumovirus.

###### Cycle threshold (Ct) values observed with three homogenization methods following mixture of identical volumes of a 1:10 or 1:1,000 dilution of inactivated MERS-CoV culture with sputum samples

![](alm-36-457-i002)

  Homogenization by     N   1:10 diluted cell culture   1:1,000 diluted cell culture                    
  --------------------- --- --------------------------- ------------------------------ ---------------- ----------------
  PK-DNase 1            3   17.6/20.9/20.2^\*^          18.1/21.1/20.4                 34.2/34.6/34.3   35.7/35.6/35.8
  PBS                   3   23.4/26.3/28.0              22.5/26.1/27.2                 34.6/34.4/Neg    35.3/35.8/Neg
  NALC-sodium citrate   3   23.0/25.6/26.0              22.5/25.6/26.0                 35.6/33.0/34.9   37.6/34.1/36.1

^\*^The 3 sputum samples shown include 1 saliva-like sputum sample, 1 non-purulent sputum sample, and 1 purulent sputum sample, with the results shown in this order.

Abbreviations: NALC, N-acetyl-L-cysteine; Neg, negative; PBS, phosphate-buffered saline; PK, proteinase K.

###### Cycle threshold (Ct) values for triplicate sputum and bronchoalveolar lavage (BAL) samples following processing using three different homogenization methods
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  Homogenization by     N^\*^   Sputum           BAL                               
  --------------------- ------- ---------------- ---------------- ---------------- ----------------
  PK-DNase 1            3       34.9/36.3/34.0   35.0/34.9/35.4   34.1/33.9/34.4   34.6/34.0/35.1
  PBS                   3       Neg/37.9/Neg     Neg/Neg/Neg      34.1/33.9/33.7   34.8/34.4/35.0
  NALC-sodium citrate   3       Neg/Neg/Neg      Neg/Neg/Neg      35.0/34.6/34.3   35.7/35.8/35.5

^\*^Three different sputum and bronchoalveolar lavage samples were included, and results are provided in this order.

Abbreviations: NALC, *N*-acetyl-L-cysteine; Neg, negative; PBS, phosphate-buffered saline; PK, proteinase K.

###### Cycle threshold (Ct) values for *upE* measured with duplicate sputum samples following processing using three homogenization methods
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  Homogenization by     Sample N (Results N)   N of positive results (%)   Ct value from positive samples, mean±SD (range)   *P* value^\*^
  --------------------- ---------------------- --------------------------- ------------------------------------------------- ---------------
  PK-DNase 1            15 (30)                30 (100)                    33.6±1.3 (31.1-35.4)                              0.11
  PBS                   15 (30)                25 (83.3)                   35.8±1.2 (34.7-39.0)                              \<0.0001
  NALC-sodium citrate   15 (30)                26 (86.7)                   35.7±1.5 (33.9-38.6)                              \<0.0001

^\*^The significance level was calculated by using the one-sample t-test. The null hypothesis was that the test mean was equal to the control mean of 33.2.

Abbreviations: NALC, *N*-acetyl-L-cysteine; PBS, phosphate-buffered saline; PK, proteinase K.
